Literature DB >> 2270484

Characterization of "peak E," a novel amino acid associated with eosinophilia-myalgia syndrome.

A N Mayeno, F Lin, C S Foote, D A Loegering, M M Ames, C W Hedberg, G J Gleich.   

Abstract

Epidemiologic studies strongly associate eosinophilia-myalgia syndrome (EMS) with ingestion of tryptophan containing a contaminant ("peak E"). Prior reports have suggested that peak E is the di-tryptophan N alpha-animal of acetaldehyde. Spectral and chemical studies now demonstrate that peak E is 1,1'-ethylidenebis[tryptophan]. This novel amino acid may be the etiological agent responsible for EMS, or it may be a marker of a still unidentified causal agent.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2270484     DOI： 10.1126/science.2270484

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  24 in total

1.  Identification of decomposition products of 1,1'-ethylidenebis [L-tryptophan], a compound associated with eosinophilia-myalgia syndrome.

Authors:  W J Driskell; D L Ashley; J Grainger; S R Sirimanne; E P Mazzola; S W Page; L L Needham; R H Hill
Journal:  Bull Environ Contam Toxicol       Date:  1992-05       Impact factor: 2.151

2.  L-Tryptophan: Biochemical, nutritional and pharmacological aspects.

Authors:  E L Sainio; K Pulkki; S N Young
Journal:  Amino Acids       Date:  1996-03       Impact factor: 3.520

3.  Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.

Authors:  Jeffrey A Allen; Alicia Peterson; Robert Sufit; Monique E Hinchcliff; J Matthew Mahoney; Tammara A Wood; Frederick W Miller; Michael L Whitfield; John Varga
Journal:  Arthritis Rheum       Date:  2011-11

4.  Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.

Authors:  R Priori; F Conti; F L Luan; C Arpino; G Valesini
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

5.  Identification of four metabolites of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in rats.

Authors:  J Adachi; T Mio; Y Ueno; T Naito; A Nishimura; S Fujiwara; K Sumino; Y Tatsuno
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

6.  Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.

Authors:  H Takagi; M S Ochoa; L Zhou; T Helfman; H Murata; V Falanga
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

7.  Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats.

Authors:  J Adachi; M Gomez; C C Smith; E M Sternberg
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

8.  A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).

Authors:  R M Silver; A Ludwicka; M Hampton; T Ohba; S A Bingel; T Smith; R A Harley; J Maize; M P Heyes
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

Review 9.  BOARD-INVITED REVIEW: Arginine nutrition and metabolism in growing, gestating, and lactating swine.

Authors:  Guoyao Wu; Fuller W Bazer; Gregory A Johnson; Yongqing Hou
Journal:  J Anim Sci       Date:  2018-12-03       Impact factor: 3.159

10.  Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.

Authors:  F Sato; Y Hagiwara; Y Kawase
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.